Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
Holding RNA?
Track your performance easily
RNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.83 - $48.80
Previous Close$44.18
Volume388.44K
Average Volume (3M)1.68M
Market Cap
$5.17B
Enterprise Value$3.88B
Total Cash (Recent Filing)$1.30B
Total Debt (Recent Filing)$8.38M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 05, 2024EPS Estimate
-$0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.95
Shares Outstanding109,801,397
10 Day Avg. Volume1,687,580
30 Day Avg. Volume1,684,369
Standard Deviation0.24
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.84
Price to Sales (P/S)439.61
Price to Cash Flow (P/CF)-17.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue366.43
Enterprise Value/Gross Profit406.25
Enterprise Value/Ebitda-14.77
Forecast
1Y Price Target
$64.38Price Target Upside47.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Avidity Biosciences News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe net loss per share was ($0.66) vs. consensus of ($0.79), indicating a better-than-expected financial performance.
Regulatory PotentialThe probability of success for del-zota has been increased to 60% in the US and 50% in the EU, reflecting strong regulatory potential.
Safety ProfileThe FDA did not take any action regarding the anaphylaxis and infusion reaction discontinuations, encouraging confidence in the drug's safety profile at higher doses.
Bears Say
Market CompetitionConcerns have been raised about increasing competition in the market.
Regulatory RisksPotential regulatory changes could negatively impact the company's operations.
Safety ConcernsOne patient discontinued due to a serious anaphylaxis event.
---
Ownership Overview
9.64% Insiders
25.54% Mutual Funds
48.77% Other Institutional Investors
16.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNA FAQ
What was Avidity Biosciences Inc’s price range in the past 12 months?
Avidity Biosciences Inc lowest stock price was $4.83 and its highest was $48.80 in the past 12 months.
What is Avidity Biosciences Inc’s market cap?
Currently, no data Available
When is Avidity Biosciences Inc’s upcoming earnings report date?
Avidity Biosciences Inc’s upcoming earnings report date is Nov 05, 2024 which is in 51 days.
How were Avidity Biosciences Inc’s earnings last quarter?
Avidity Biosciences Inc released its earnings results on Aug 09, 2024. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.756 by $0.106.
Is Avidity Biosciences Inc overvalued?
According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued.
Does Avidity Biosciences Inc pay dividends?
Avidity Biosciences Inc does not currently pay dividends.
What is Avidity Biosciences Inc’s EPS estimate?
Avidity Biosciences Inc’s EPS estimate is -$0.72.
How many shares outstanding does Avidity Biosciences Inc have?
Avidity Biosciences Inc has 117,121,400 shares outstanding.
What happened to Avidity Biosciences Inc’s price movement after its last earnings report?
Avidity Biosciences Inc reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.756. Following the earnings report the stock price went down -5.261%.
Which hedge fund is a major shareholder of Avidity Biosciences Inc?
Among the largest hedge funds holding Avidity Biosciences Inc’s share is RA Capital Management. It holds Avidity Biosciences Inc’s shares valued at 221M.
---
Avidity Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.38 (47.26% Upside)
$64.38 (47.26% Upside)
Blogger Sentiment
Bullish
RNA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
452.25%
12-Months-Change
Fundamentals
Return on Equity
-28.36%
Trailing 12-Months
Asset Growth
120.61%
Trailing 12-Months
Company Description
Avidity Biosciences Inc
Avidity Biosciences Inc is a bio-technology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.
---
RNA Stock 12 Month Forecast
Average Price Target
$64.38
▲(47.26% Upside)
Technical Analysis
Seres Therapeutics
―
Arrowhead Pharmaceuticals
―
Crispr Therapeutics AG
―
Alnylam Pharma
―
Best Analysts Covering RNA
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+178.10%
reiterated a buy rating last month
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +178.10% per trade.
---